Cost‐effectiveness of alternating magnetic resonance imaging and digital mammography screening in <i>BRCA1</i> and <i>BRCA2</i> gene mutation carriers

Abstract

Alternating MRI and DM screening at 6-month intervals beginning at age 30 years was identified as a clinically effective approach to applying current guidelines, and was more cost-effective in BRCA1 gene mutation carriers compared with BRCA2 gene mutation carriers.